Free Trial

Exagen (XGN) Competitors

Exagen logo
$6.86 +0.03 (+0.44%)
As of 11:00 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

XGN vs. CSTL, PSNL, INNV, EHAB, SBC, CELC, AUNA, TALK, OMDA, and FTRE

Should you be buying Exagen stock or one of its competitors? The main competitors of Exagen include Castle Biosciences (CSTL), Personalis (PSNL), InnovAge (INNV), Enhabit (EHAB), SBC Medical Group (SBC), Celcuity (CELC), Auna (AUNA), Talkspace (TALK), Omada Health (OMDA), and Fortrea (FTRE). These companies are all part of the "healthcare" industry.

Exagen vs. Its Competitors

Exagen (NASDAQ:XGN) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

75.3% of Exagen shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 12.6% of Exagen shares are owned by company insiders. Comparatively, 6.5% of Castle Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Castle Biosciences has higher revenue and earnings than Exagen. Castle Biosciences is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exagen$55.64M2.63-$15.11M-$0.84-8.17
Castle Biosciences$347.08M1.68$18.25M-$0.19-106.05

In the previous week, Castle Biosciences had 2 more articles in the media than Exagen. MarketBeat recorded 2 mentions for Castle Biosciences and 0 mentions for Exagen. Castle Biosciences' average media sentiment score of 1.70 beat Exagen's score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Exagen Neutral
Castle Biosciences Very Positive

Exagen has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Exagen presently has a consensus price target of $7.50, indicating a potential upside of 9.33%. Castle Biosciences has a consensus price target of $37.00, indicating a potential upside of 83.63%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Exagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exagen
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Castle Biosciences
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

Castle Biosciences has a net margin of -1.46% compared to Exagen's net margin of -27.34%. Castle Biosciences' return on equity of 3.41% beat Exagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Exagen-27.34% -133.69% -34.87%
Castle Biosciences -1.46%3.41%2.95%

Summary

Castle Biosciences beats Exagen on 11 of the 15 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Sign up to receive the latest news and ratings for XGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XGN vs. The Competition

MetricExagenMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$146.12M$10.54B$5.59B$8.99B
Dividend YieldN/A2.09%5.25%4.03%
P/E Ratio-8.1716.5927.5420.13
Price / Sales2.6331.46415.83172.83
Price / CashN/A22.7937.0657.97
Price / Book12.703.768.105.61
Net Income-$15.11M$235.43M$3.17B$248.50M
7 Day Performance1.86%3.69%3.33%4.36%
1 Month Performance-6.79%3.98%3.54%6.87%
1 Year Performance268.82%-10.14%33.62%20.78%

Exagen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XGN
Exagen
3.6462 of 5 stars
$6.86
+0.4%
$7.50
+9.3%
+261.4%$146.12M$55.64M-8.17220
CSTL
Castle Biosciences
3.0331 of 5 stars
$20.42
+0.3%
$37.00
+81.2%
+12.7%$587.55M$332.07M-107.47540Positive News
PSNL
Personalis
3.5106 of 5 stars
$6.56
-0.3%
$7.67
+16.9%
+380.5%$581.18M$85.69M-5.09400News Coverage
Positive News
INNV
InnovAge
0.8805 of 5 stars
$3.69
-5.9%
$5.00
+35.5%
-17.7%$529.25M$763.85M-16.042,350
EHAB
Enhabit
2.7269 of 5 stars
$9.64
+0.8%
$8.75
-9.2%
-17.3%$484.09M$1.03B-3.4810,700News Coverage
Positive News
SBC
SBC Medical Group
N/A$4.64
flat
N/AN/A$480.76M$205.42M0.00N/AHigh Trading Volume
CELC
Celcuity
1.9868 of 5 stars
$13.35
+6.5%
$30.80
+130.7%
-21.1%$474.84MN/A-4.4140
AUNA
Auna
3.3157 of 5 stars
$6.20
-2.2%
$10.70
+72.6%
-19.4%$469.24M$1.17B10.6914,842High Trading Volume
TALK
Talkspace
3.9464 of 5 stars
$2.78
+0.4%
$4.50
+61.9%
+29.3%$463.46M$187.59M139.07500Positive News
OMDA
Omada Health
N/A$18.30
+3.9%
N/AN/A$453.46MN/A0.00849Analyst Forecast
FTRE
Fortrea
3.8828 of 5 stars
$4.94
-0.8%
$15.00
+203.6%
-78.3%$450.69M$2.70B-0.5615,500Analyst Forecast

Related Companies and Tools


This page (NASDAQ:XGN) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners